OBJECTIVES The purpose of this study was to evaluate the effectiveness and safety of treatment with recombinant growth hormone (RGH) in children with GH deficiency. METHODS This was an interventional study with 6 and 12 months follow-up. Treatment was received by 15 children. The patients were receiving the RGH in 0.033 mg/kg (0.1 Unit/kg) at the same time each day (9-10 pm) for period of 1 year.  The effectiveness of treatment was evaluated based on change in growing speed, growth SDS and bone age maturation. RESULTS The mean age of children was 9.5±3.6 years . In the given sample 6 children had MHPD, other 9 children had IGHD.  There was a great improvement in absolute growth at 6 and 12 months period of treatment (p-0.001; p-0.001).The same was found for growth SDS (p-0.001; p-0.001). Effectiveness of RGH therapy on bone age maturation also showed great improvement (p-0.001; p-0.001). The level of IGF-1 was increased (p-0.001; p-0.001); at 12 months the level of IGF-1 reached to 248.72±70.7 ng/mL  and remained consistently high. The same improvement was in IGF-pb3 levels (p-0.001; p-0.001). The lipidemic analysis showed that the blood cholesterol levels were from 3.21 to 12.39 mmol/L (norm 5.68±1.55 mmol/L) and the level of LDL - 1.3 to 10.86 mmol/L ( norm 3.83±1.44 mmol/L). During the treatment period we observed the significant improvement in cholesterol levels (p-0.001; p-0.001). High density lipoprotein and triglyceride   levels did not change significantly (p.0.05). CONCLUSIONS It can be concluded that the treatment with RGH in patient with GH deficiency is beneficial as it normalized the levels of cholesterol and LDL. During the treatment there were no any changes in indicators of kidney’s function, indicators of liver’s function as well as the indicators of carbohydrate metabolism.